Gilead Receives Criticism For Efforts To Keep Generic HCV Drug From Being Diverted To Developed Countries

Financial Times: Pharma combats diversion of cheap drugs
“…[A]s the first Indian-made generics [of Gilead’s hepatitis C drug Solvadi] start to roll off the production lines, Gilead is coming in for heavy criticism. Médecins Sans Frontières, the medical charity, is accusing the U.S. group of promoting overly-intrusive patient surveillance to stop the generic, called sofosbuvir, being diverted to patients in developed countries where the drug is more costly and tightly rationed by strained public health systems…” (Kazman, 4/12).